Liquid metals as electrodes in polymer light emitting diodes

We demonstrate that liquid metals can be used as cathodes in light emitting diodes (pLEDs). The main difference between the use of liquid cathodes and evaporated cathodes is the sharpness of the metal–polymer interface. Liquid metal cathodes result in significantly sharper metal–organic interfaces than vapor deposited cathodes, due to the high surface energy of the metals. The sharper interface in pLEDs with liquid metal cathodes is observed by neutral impact collision ion scattering spectroscopy and low energy ion scattering spectroscopy measurements. The influence of interface sharpness on device performance was studied by comparing current–voltage-light characteristics of devices with OC1C10 paraphenylenevinylene (PPV) as electroluminescent polymer and indium tin oxide (ITO) as hole injection electrode, and different cathodes. Comparison of devices using a liquid Ga cathode and an evaporated Al cathode showed that light emission for the liquid Ga cathode is two orders of magnitude larger than for the evaporated Al cathode, and that the external light efficiency is increased by an order of magnitude. Since the work function of Ga and Al is nearly the same, the poor performance for evaporated Al LEDs is attributed to the formation of an interfacial layer where Al has diffused into, and reacted with, the PPV. This interfacial layer has poor electrical conduction compared to pure PPV, and contains quenching sites which reduce light emission. Low work function liquid metal cathodes were studied by using liquid Ca and Ba amalgams. The improved performance of liquid amalgam pLEDs is attributed to the different structure of the metal–polymer interface. The enormous increase in light and current through the amalgam devices compared to those using pure Hg demonstrate that less than 1 ML of a metal with a low work function at the polymer-cathode interface can have a dramatic effect on the performance of the devices. Devices with a liquid Ca amalgam cathode showed an increase of the current (by 50%) and brightness (80%) compared to devices with an evaporated Ca cathode, which is ascribed to reduced diffusion of Ca into the emissive PPV laye

Sensory and motor neuronopathy in a patient with the A382P TDP-43 mutation

Patients with TARDBP mutations have so far been classified as ALS, sometimes with frontal lobe dysfunction. A 66-year-old patient progressively developed a severe sensory disorder, followed by a motor disorder, which evolved over nine years. Symptoms started in the left hand and slowly involved the four limbs. Investigations were consistent with a mixed sensory and motor neuronopathy. A heterozygous change from an alanine to a proline at amino acid 382 was identified in exon 6 of the TARDPB gene (p.A382P). This case expands the phenotypic spectrum associated with mutations in the TARDBP gene and shows that sensory neurons can be severely damaged early in the course of the disease, following a propagating process, with an orderly progression from a focal starting point. A combination of severe sensory and motor neuronopathy is rarely encountered in clinical practice. The possibility of an A382P TDP-43 mutation should be considered in patients with such an association

Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial

<p>Abstract</p> <p>Background</p> <p>Highly active antiretroviral therapy produces a significant decrease in HIV-1 replication and allows an increase in the CD4 T-cell count, leading to a decrease in the incidence of opportunistic infections and mortality. However, the cost, side effects and complexity of antiretroviral regimens have underscored the immediate need for additional therapeutic approaches. Statins exert pleiotropic effects through a variety of mechanisms, among which there are several immunoregulatory effects, related and unrelated to their cholesterol-lowering activity that can be useful to control HIV-1 infection.</p> <p>Methods/design</p> <p>Randomized, double-blinded, placebo controlled, single-center, phase-II clinical trial. One hundred and ten chronically HIV-1-infected patients, older than 18 years and naïve for antirretroviral therapy (i.e., without prior or current management with antiretroviral drugs) will be enrolled at the outpatient services from the most important centres for health insurance care in Medellin-Colombia. The interventions will be lovastatin (40 mg/day, orally, for 12 months; 55 patients) or placebo (55 patients). Our primary aim will be to determine the effect of lovastatin on viral replication. The secondary aim will be to determine the effect of lovastatin on CD4+ T-cell count in peripheral blood. As tertiary aims we will explore differences in CD8+ T-cell count, expression of activation markers (CD38 and HLA-DR) on CD4 and CD8 T cells, cholesterol metabolism, LFA-1/ICAM-1 function, Rho GTPases function and clinical evolution between treated and not treated HIV-1-infected individuals.</p> <p>Discussion</p> <p>Preliminary descriptive studies have suggested that statins (lovastatin) may have anti HIV-1 activity and that their administration is safe, with the potential effect of controlling HIV-1 replication in chronically infected individuals who had not received antiretroviral medications. Considering that there is limited clinical data available on this topic, all these findings warrant further evaluation to determine if long-term administration of statins may benefit the virological and immunological evolution in HIV-1-infected individuals before the use of antiretroviral therapy is required.</p> <p>Trial registration</p> <p>Registration number NCT00721305.</p